Ember LifeSciences Taps Amgen Vet for CFO in Cold Chain Disruption

LOS ANGELES, CA – January 21, 2026 – Fresh off a $16.5 million Series A funding round, Ember LifeSciences, Inc. is bolstering its executive team with a significant hire from the pharmaceutical industry. The company, a pioneer in temperature-controlled logistics, announced today the appointment of Ann Hyllengren, a nearly two-decade veteran of Amgen, as its new Chief Financial Officer. The move signals a clear intent to accelerate growth and scale its operations as it aims to solve one of healthcare's most persistent and costly problems: the failure of the pharmaceutical cold chain.

A Strategic Hire for an Ambitious Growth Phase

The appointment of Hyllengren is a strategic maneuver designed to leverage deep industry expertise as Ember LifeSciences enters its next critical phase. The company's recent financing, which closed in December and included investors like Carrier and Gozde Tech Ventures, is earmarked for developing next-generation products and expanding its global footprint. Hyllengren's background makes her uniquely qualified to steer the company's financial strategy through this expansion.

During her extensive tenure at Amgen, one of the world's leading biotechnology companies, Hyllengren held several high-impact senior leadership roles. She served as head of finance for the multibillion-dollar U.S. General Medicine business unit, where she was instrumental in shaping product strategy, resource allocation, and profitability analysis. Her experience also includes managing a $1 billion annual capital portfolio and serving as a senior executive on Amgen's Investor Relations team, translating complex financial data into a compelling narrative for the capital markets.

"We are thrilled to welcome Ann at a pivotal stage in our evolution," said Clay Alexander, founder and CEO of Ember LifeSciences. "She brings deep financial and operational leadership experience at one of the top life science companies in the world and will be instrumental as we develop and launch new reliable, sustainable cold chain solutions for life sciences, and beyond."

Beyond her corporate roles, Hyllengren also served as the Chief Financial Officer for the Amgen Foundation, where she oversaw major initiatives supporting STEM education. Her transition from a pharmaceutical giant to a disruptive technology provider underscores the growing importance of innovation in the healthcare supply chain.

Tackling the $35 Billion Cold Chain Challenge

Ember LifeSciences is targeting a massive and notoriously fragile segment of the global economy. The pharmaceutical cold chain—the system of transporting temperature-sensitive products like vaccines, biologics, and cell and gene therapies—is valued at over $16 billion and is projected to nearly double by 2032. However, this critical infrastructure is plagued by inefficiency. An estimated $35 billion is lost annually due to "temperature excursions," where products are exposed to conditions outside their required range, rendering them ineffective and unsafe.

These failures not only result in staggering financial losses but also risk patient health and create significant waste. The industry has traditionally relied on single-use, passive shipping solutions, such as Styrofoam coolers packed with ice or gel packs. These methods offer limited temperature control, no real-time visibility, and generate millions of pounds of landfill waste each year. As therapies become more complex and valuable, the need for a more reliable and intelligent solution has become urgent.

From Smart Mugs to Life-Saving Shippers

The technology at the heart of Ember LifeSciences' solution has a unique and proven origin. The company is a 2022 spin-off of Ember Technologies, the design-led brand famous for its award-winning temperature control mugs. Having sold over half a billion dollars' worth of its consumer products, Ember Technologies established itself as a leader in personal thermal management.

Founder and CEO Clay Alexander saw an opportunity to apply the company's proprietary technology and intellectual property to a far more critical problem. The idea for Ember LifeSciences was born from conversations with healthcare leaders about the potential for Ember's core technology to save lives by revolutionizing how medicines are transported. This strategic pivot leverages a proven platform for a high-stakes market, moving from enhancing daily coffee enjoyment to ensuring the viability of life-saving treatments. The Ember Cube was the company's first foray into healthcare, developed initially in partnership with distribution leader Cardinal Health before the formal spin-off.

The Ember Cube: A Sustainable, Data-Driven Solution

At the center of the company's strategy is the Ember Cube, which it bills as the world's first self-refrigerated, cloud-based digital shipping box. Unlike passive coolers, the Cube uses an active, thermoelectric refrigeration system to maintain a precise internal temperature, typically between 2°C and 8°C, for more than 72 hours on a single charge.

Its true differentiation lies in its connectivity. Each Cube is equipped with an onboard cellular radio that transmits real-time data to a cloud-based dashboard. Shippers have constant visibility into the package's GPS location, internal temperature, and humidity. This data stream allows for proactive intervention; if an algorithm predicts a potential temperature deviation due to a shipping delay, stakeholders can be alerted before the product is compromised.

Sustainability is another core pillar of the Cube's design. The device is built to be reused hundreds of times, directly addressing the waste generated by single-use packaging. This is enabled by a "return-to-sender" feature. Once the medicine is delivered and removed, a healthcare provider can press a button on the Cube. This action automatically generates a return shipping label on the device's built-in e-ink screen and alerts a carrier for pickup using its GPS location. Leaders at Ember and its partner Cardinal Health estimate the system could prevent 7 million pounds of medical shipping waste from reaching landfills annually.

"I am excited to join a team that is working to solve one of the healthcare industry's most costly challenges, with a clear focus on sustainability and improving patient outcomes," said Ann Hyllengren. "Ember is creating a disruptive and positive impact across the life sciences supply chain, and I look forward to supporting the company's operational scale and market expansion."

With its recent funding and new financial leadership, Ember LifeSciences is now focused on scaling production and enhancing its technology. The company is already developing the Ember Cube 2, a next-generation model that will use highly efficient vacuum insulation and proprietary bio-based phase change materials to further improve performance and sustainability as it pushes for wider adoption in global markets.